Eu Adopts Positive Opinion on Levemir as an Add-On Therapy to Victoza in Type 2 Diabetes Patients

Following a review of new data from a  52-week clinical trial, the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir, as add-on therapy to Novo Nordisk’s GLP-1 analogue, Victoza, in combination with metformin in patients with type 2 diabetes.
The CHMP also adopted a positive opinion for Victoza. Although the CHMP did not consider the results of the study sufficient to support a new indication for Victoza, the Committee concluded that the new data were of importance to healthcare professionals involved in treating type 2 diabetes and recommended that they be included in the product information for Victoza. 
The 52-week, randomized, open-label clinical trial was conducted to evaluate the safety and efficacy of adding once-daily Levemir to treatment with Victoza 1.8 mg plus metformin. 
Key findings from the study include:
  • After completing 12 weeks of treatment with Victoza and metformin, 61% of patients reached the ADA target for blood sugar control (HbA1C <7%) with mean decreases in HbA1C of 1.3% and body weight of 4.4 kg (9.7 lbs)
  • After the additional 26 weeks, patients randomized to add on Levemir to Victoza and metformin had further HbA1C reductions of 0.5%, while HbA1C remained stable in the Victoza and metformin group
  • Furthermore, 43% of patients in the Victoza, metformin and Levemir group reached the ADA target for blood sugar control (HbA1C <7%) at 26 weeks vs an additional 17% in the Victoza and metformin group
  • Weight loss was sustained after Levemir was added.
Novo Nordisk anticipates that the European Commission, within the coming months, will approve the usage of Levemir as an add-on therapy to Victoza in patients with type 2 diabetes. 
Notify of
Inline Feedbacks
View all comments
Copyright © 2009-2021 Diabetes Media Foundation, All Rights Reserved.
ASweetLife™ is a trademark of the Diabetes Media Foundation, All Rights Reserved.
Would love your thoughts, please comment.x